MyPath: Developing and implementing innovative Patient-Centred Care Pathways for cancer patients

在欧盟，2020年有270万人被诊断出患有癌症，130万人死于癌症。多亏了早期发现和新疗法的进步，超过1200万人在癌症中幸存下来。随着更高的治愈率和更多的癌症患者存活时间更长，获得以患者为中心的护理变得越来越重要，这些护理包括最佳的支持性、姑息性、存活率和临终护理。然而，癌症护理仍然存在孤岛，直到今天，仍然没有适用于不同文化、环境和环境的技术支持。几个随机对照试验提供的证据表明，将以患者为中心的护理与标准肿瘤学护理相结合，可以产生更好的患者和护理者结果。到目前为止，这些发现还没有转化为临床常规。在这个项目中，我们将开发技术增强和基于证据的以患者为中心的护理路径，称为MyPath，将与以肿瘤为中心的治疗相结合，涵盖支持性、姑息性、存活期和临终关怀。MyPath整合了OUS EIR软件的患者报告结果，将通过著名的欧洲肿瘤学家、伦理学家、心理学家和社会学家的贡献进一步推进。它将在我们的中小企业合作伙伴DNV Imatis的eHealth平台上配置。其有效性和可持续性将在欧洲9个临床中心的实施科学研究中进行评估。在领先的癌症护理专业协会ESMO和EAPC以及癌症患者组织ECPC的支持下，我们致力于在合适的时间由合适的人向合适的人提供合适的护理。我们假设MyPath可以显著提高治疗和护理的质量和获得机会，减少临床实践中的差异，并优化家庭、社区和医院护理环境中的资源。这最终将减少与癌症相关的身体、情感和最终的经济负担。

In the EU, 2.7M people were diagnosed with and 1.3M died of cancer in 2020. Over 12M people have survived cancer, thanksto advances in early detection and new therapies. With higher cure rates and more patients living longer with cancer, access to patient-centred care consisting of optimal supportive, palliative, survivorship and end-of-life care becomes increasingly important. However, cancer care still has silos, and to this day, there is no technical support available that is suitable for different cultures, settings and environments. Several randomised controlled trials have provided evidence that the integration of patient-centred care in standard oncology care results in better patient and caregiver outcomes. As yet, these findings have not translated into clinical routine. In this project, we will develop technology-enhanced and evidence-based patient-centred care pathways, called MyPath, to be merged with tumour-centred treatments across supportive, palliative, survivorship and end-of-life care. MyPath integrates patient-reported outcomes of the OUS Eir software, to be further advanced with contributions of renowned European oncologists, ethicists, psychologists and sociologists. It will be configurated on the eHealth platform of our SME partner DNV Imatis. Its effectiveness and sustainability will be assessed in an implementation science study in 9 clinical centres across Europe. With the support of leading cancer care professional associations ESMO and EAPC, and the cancer patient organisation ECPC, we are committed to delivering the right care to the right person at the right time by the right persons. We hypothesise that MyPath can significantly improve the quality of and access to treatment and care, reduce variations in clinical practice, and optimise resources in family, community, and hospital care settings. This will ultimately reduce the physical, emotional, and ultimately economic burden linked to cancer.